Paradigm Biopharmaceuticals Ltd has released a press release.
PAR Capital Raising Presentation
Filed with ASX ·
6ix hasn’t read this filing yet.
Paradigm Biopharmaceuticals Ltd. on 6ix
In the deck
Earlier from Paradigm Biopharmaceuticals
- Successful Completion of $16M Placement for Phase 3
- Trading Halt
- Paradigm to Proceed with Phase 3 Knee OA Trial
- Response to ASX Price Query
- 2024 Chairman Address and AGM Presentation
Later from Paradigm Biopharmaceuticals
- Paradigm Receives $6.3m R&D Tax Refund
- Quarterly Activities/Appendix 4C Cash Flow Report
- PAR Selects Advanced Clinical as CRO for Phase 3
- Loyalty and Piggyback Options Program
- Paradigm Secures Ethics Approval for Phase 3 Trial
Follow Paradigm Biopharmaceuticals into a list and get an email when it puts out news.
Follow Paradigm Biopharmaceuticals